Graeme MacLennan

Oct 12, 2023 | jamanetwork.com | Jan Jansen |Claire Cochran |Graeme MacLennan |Robbie Lendrum

Key PointsQuestion  Does the addition of resuscitative endovascular balloon occlusion of the aorta (REBOA) to standard care reduce mortality in trauma patients with exsanguinating hemorrhage? Findings  In this bayesian randomized clinical trial that included 89 patients at 90 days, all-cause mortality was 54% in the REBOA and standard care group vs 42% in the standard care alone group (odds ratio, 1.58; posterior probability of increased odds of death with REBOA, 86.9%).